Meet our partners
Europe Partner
Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Read more at amgen.com
News

Feb 2016 New Drug Treatment Kyprolis® (carfilzomib) for Relapsed Multiple Myeloma Launches in the UK

Sep 2015 Cholesterol Lowering Treatment Repatha Evolocumab Offers New Way To Help UK Patients

Aug 2015 Minister Bruton Opens New 300 Million Amgen Facility


OneStart Europe Vision Film 2016

  • Georg Buchner, Licensing Director, Amgen 
  • Dan Perez, CEO & Founder, Oxbridge Biotech Roundtable 
  • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
  • Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson 
  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC
  • Matthew Foy, Partner, SR One
  • Sarah Haywood, CEO, MedCity 
  • Matthias Essenpreis, CTO (Diagnostics), F-Hoffman-La Roche Ltd. 
  • Rachel Moss, Associate Principal, McKinsey and Company 
  • Claire Brown, Investment Manager, Alderley Park Ventures / BioCity 
  • Lynne Murray, Partnering and Strategy, MedImmune
  • Aric Orbach, Head of Pharmacology, Teva Pharmaceutical Industries 
  • Stephen Reese, Partner, Olswang LLP 
  • Ilan Zipkin, Investment Director, Takeda Ventures Inc. 


From the OneStart London Bootcamp 2016 

Panel Discussion

Panel Discussion: Accessing and Interacting with Industry
  • Rachel Moss, PhD, Associate Prinicipal, McKinsey and Company (Chair) 
  • Georg Buchner, PhD MBA, Licensing Director, Amgen 
  • Elena Fernandez-Kleinlein, Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation London 
  • Will West, PhD, President & CEO, Cancer Targeting Systems Inc. 
  • Claire Brown, PhD, Investment Manager, Alderley Park Ventures / BioCity 
  • Aric Orbach, DVM, Head of Pharmacology, Teva Pharmaceutical Industries 


Panel Discussion: Navigating Critical Decision Points
  • Lynne Murray, PhD, MBA, Partnering & Strategy, MedImmune (Chair)
  • Georg Buchner, PhD MBA, Licensing Director, Amgen 
  • Sarah Holland, DPhil (Oxon), MBA, External Science and Partnering, Sanofi
  • Matthias Essenpreis, PhD, Chief Technology Officer (Diagnostics), F.Hoffmann-La Roche Ltd.
  • Jonathan Tobin, PhD, MBA, Principal, Healthcare Venture, Imperial Innovations
  • Mentors
    Georg Buchner
    Licensing Director Europe & Israel, Amgen + more
    A highly motivated business minded professional with excellent communication-and-interpersonal skills and international experience. My scientific background, sound commercial experience, and ability to network have accelerated my progression from science, through consulting to business development & licensing have enabled me to build strategic relationships across the life sciences industry and close a reasonable number of deals. I am an Italian and German native speaker and have a PhD and a post-doc from Kings College London and MBA from University of Cambridge. I am committed to pursue a career in business and corporate development in the life sciences industry. Specialties: technology-product licensing, scouting, termsheet- contracts negotiation, presentation skills, networking, strategic and financial analysis and modelling of licensing opportunities, e.g market research, competitor and benchmarking analysis, risk-adjusted NPV-based deal valuation, business-marketing plans, M&A, account management, business development, scientific and commercial analysis.
    Tracy Blois
    Head of Business Development Operations at Amgen + more
    Biochemist turned business development professional with broad interests in bridging communication between those in business and those in science. Committed to inspiring the next generation of scientists through involvement in scientific outreach and education. Specialties: Team leadership and taking initiative, Project management, Scientific communication, Biochemistry and Molecular Biology, Membrane protein folding.
    Teams Mentored